Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

NCT04137107 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT04137107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04137107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 17, 2020
Completion date
December 31, 2026
Enrollment
220 (actual)
Sites
793

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii colorectal cancer ajcc v8, stage iii colorectal cancer ajcc v8